Source:http://linkedlifedata.com/resource/pubmed/id/12656892
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
6
|
pubmed:dateCreated |
2003-3-26
|
pubmed:commentsCorrections | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Apr
|
pubmed:issn |
1464-4096
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
91
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
464-5
|
pubmed:dateRevised |
2006-7-18
|
pubmed:meshHeading | |
pubmed:year |
2003
|
pubmed:articleTitle |
Zoledronic acid: a new advance in managing skeletal events in prostate cancer.
|
pubmed:affiliation |
St George's Hospital, London, UK.
|
pubmed:publicationType |
Journal Article,
Comment
|